Global Cancer Burden and Epidemiology Analysis by Age Group, 2026-2035

Description

Cancer remains one of the leading causes of morbidity and mortality worldwide, posing substantial challenges for healthcare systems, governments, and research organizations. The global cancer burden continues to increase due to demographic transitions, longer life expectancy, population growth, lifestyle-related risk factors, environmental exposures, and advances in diagnostic capabilities. While cancer can affect individuals at any age, incidence patterns, disease characteristics, treatment approaches, survival outcomes, and healthcare needs vary significantly across different age groups. Consequently, age-specific epidemiological analysis has become an essential component of cancer research, healthcare planning, drug development, and public health policy formulation.

Cancer burden and epidemiology analysis by age group provides comprehensive insights into disease prevalence, incidence, mortality, survival rates, risk factors, healthcare utilization, and future patient population forecasts across pediatric, adolescent, adult, and geriatric populations. These analyses support evidence-based decision-making for healthcare providers, pharmaceutical companies, regulatory agencies, public health organizations, and policymakers seeking to address the growing global cancer burden.

Market Drivers

Increasing Global Cancer Incidence

One of the primary drivers of market growth is the continued rise in global cancer incidence. Population growth and demographic aging have contributed significantly to increasing numbers of cancer diagnoses worldwide. As healthcare systems confront expanding cancer patient populations, demand for detailed epidemiological intelligence and age-specific disease burden assessments continues to grow.

Understanding how cancer incidence varies across age groups is critical for developing targeted prevention strategies, optimizing healthcare resources, and improving patient outcomes.

Aging Population Worldwide

Population aging is one of the most significant contributors to cancer burden globally. The majority of cancer diagnoses occur among older adults due to cumulative exposure to carcinogenic factors, age-related biological changes, and declining immune surveillance.

As the proportion of elderly individuals increases across many countries, healthcare systems are expected to experience growing demand for oncology services, geriatric cancer care, and age-specific disease forecasting. This trend is driving increased investment in epidemiological research focused on older populations.

Growing Focus on Pediatric and Adolescent Oncology

Although cancer is less common among children and adolescents compared to adults, pediatric cancers remain a major public health concern due to their unique biological characteristics, treatment requirements, and long-term survivorship issues.

Increasing awareness of childhood cancer burden and improvements in cancer registries are contributing to greater demand for age-specific epidemiological analyses covering pediatric and adolescent populations.

Expansion of Cancer Registries and Real-World Data Sources

The growing availability of cancer registries, electronic health records, genomic databases, mortality registries, insurance claims data, and population health platforms is improving the quality and accessibility of epidemiological information.

These data sources enable more detailed assessments of age-related cancer patterns, survival outcomes, treatment utilization, and future disease forecasts, supporting market growth.

Market Restraints

Variability in Data Quality Across Regions

Differences in healthcare infrastructure, cancer registry coverage, diagnostic capabilities, and reporting standards can create inconsistencies in epidemiological datasets.

These variations may limit the comparability of age-specific cancer burden estimates across countries and regions.

Underdiagnosis in Resource-Limited Settings

Many low- and middle-income countries continue to face challenges related to cancer detection, diagnostic access, and healthcare infrastructure. Consequently, cancer cases may be underreported in certain age groups, affecting the accuracy of epidemiological assessments.

Complexity of Age-Specific Disease Patterns

Cancer epidemiology varies considerably across age groups, cancer types, geographic regions, genetic backgrounds, and environmental exposures. This complexity can increase analytical challenges and require sophisticated epidemiological modeling techniques.

Technology and Segment Insights

The global cancer burden and epidemiology analysis by age group market can be segmented by age group, cancer type, data source, application, end user, and geography.

By age group, the market includes pediatric populations (0-14 years), adolescents and young adults (15-39 years), adults (40-64 years), and geriatric populations (65 years and above). The geriatric segment accounts for the largest share due to the significantly higher incidence of most cancers among older individuals. However, increasing research attention toward pediatric and young adult cancers is supporting growth across younger age categories.

By cancer type, the market includes breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, pancreatic cancer, ovarian cancer, cervical cancer, hematological malignancies, brain tumors, pediatric cancers, and other malignancies. Age-specific epidemiological analyses are particularly important for understanding variations in disease incidence, treatment outcomes, and survival across these cancer categories.

By data source, the market includes cancer registries, hospital databases, electronic health records, insurance claims databases, mortality databases, genomic databases, population health surveys, and public health surveillance systems. Cancer registries remain among the most important sources of epidemiological intelligence due to their comprehensive disease tracking capabilities.

By application, the market includes incidence analysis, prevalence assessment, mortality analysis, survival analysis, patient population forecasting, healthcare planning, public health policy development, clinical research support, and pharmaceutical market assessment. Patient population forecasting and healthcare resource planning represent significant application areas due to increasing healthcare system demands.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, government agencies, public health organizations, contract research organizations, and healthcare consulting firms. Government agencies and public health organizations remain major users because of their responsibilities for disease surveillance and healthcare planning.

Technological advancements are transforming epidemiological analysis through artificial intelligence, machine learning, predictive analytics, population health modeling, real-world evidence platforms, and advanced statistical tools. These technologies enable more accurate disease forecasting, age-specific risk assessment, and identification of emerging epidemiological trends.

The integration of genomic data, molecular profiling information, lifestyle factors, environmental exposure data, and healthcare utilization records is creating more comprehensive epidemiological models that support precision public health initiatives and targeted cancer prevention programs.

Geographically, North America dominates the market due to advanced healthcare infrastructure, comprehensive cancer registries, extensive oncology research activities, and strong investments in population health analytics. Europe maintains a substantial market position supported by established public health systems and collaborative cancer surveillance programs. Asia-Pacific is expected to experience the fastest growth due to increasing cancer incidence, aging populations, expanding healthcare infrastructure, and growing investments in cancer research across countries such as China, Japan, India, and South Korea. Latin America and the Middle East & Africa are also improving cancer surveillance capabilities and strengthening epidemiological research initiatives.

Competitive and Strategic Outlook

The competitive landscape includes epidemiology research organizations, healthcare analytics providers, academic research institutions, public health agencies, cancer research centers, contract research organizations, and healthcare intelligence companies. Market participants are increasingly investing in advanced analytics technologies, real-world evidence platforms, artificial intelligence-based forecasting tools, and integrated population health solutions.

Strategic collaborations among governments, healthcare providers, research institutions, pharmaceutical companies, and technology firms are becoming increasingly common as stakeholders seek to improve cancer surveillance, patient population forecasting, and healthcare planning capabilities.

Organizations are also expanding investments in precision medicine research, cancer registries, and age-specific disease intelligence solutions to address the growing complexity of oncology care and population health management.

Conclusion

The global cancer burden and epidemiology analysis by age group market is poised for strong growth through 2031, supported by rising cancer incidence, aging populations, expanding healthcare data infrastructure, and increasing demand for age-specific epidemiological intelligence. Understanding cancer patterns across different age groups is becoming increasingly important for healthcare planning, drug development, public health policy, and resource allocation. While challenges related to data quality, underreporting, and epidemiological complexity remain, advances in artificial intelligence, real-world evidence analytics, and population health technologies are expected to significantly enhance disease surveillance and forecasting capabilities. As the global cancer burden continues to grow, age-specific epidemiological analysis will play an increasingly important role in supporting evidence-based healthcare decisions and improving patient outcomes.

Key Benefits of this Report

Insightful Analysis: Comprehensive evaluation of cancer incidence, prevalence, mortality, survival, and patient populations across different age groups.
Competitive Landscape: Understand emerging epidemiological trends, research initiatives, and analytical methodologies shaping the market.
Market Drivers and Future Trends: Assess key growth factors and technological advancements influencing cancer surveillance and healthcare planning.
Actionable Recommendations: Support healthcare policy development, oncology resource allocation, prevention strategies, and investment decisions.
Caters to a Wide Audience: Suitable for pharmaceutical companies, healthcare providers, public health agencies, academic institutions, consultants, and investors.

What Businesses Use Our Reports For

Patient population forecasting, disease burden assessment, epidemiological intelligence, healthcare planning, oncology market evaluation, clinical research support, public health policy development, investment analysis, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Global, regional, and country-level incidence, prevalence, mortality, survival, and patient population analysis by age group
Cancer type-specific epidemiological trends, risk factor assessments, and disease burden forecasting
Healthcare policy evaluation, population health insights, and oncology planning strategies
Competitive intelligence, research developments, and future market opportunity assessment.

Product Code: KSI-008859

1. Executive Summary

1.1 Report Scope and Objectives
1.2 Key Findings
1.3 Global Cancer Epidemiology Overview by Age Group
1.4 Key Trends in Cancer Incidence and Mortality
1.5 Age-Specific Burden Analysis
1.6 Screening and Early Detection Trends
1.7 Treatment Access and Healthcare Utilization Trends
1.8 Key Growth Drivers and Challenges
1.9 Regional Highlights
1.10 Future Outlook and Strategic Insights

2. Disease & Epidemiology Analysis

2.1 Introduction to Cancer Epidemiology
2.2 Definition and Classification of Cancer
2.3 Methodology for Epidemiological Assessment
2.4 Burden of Cancer by Age Group
- 2.4.1 Pediatric Population (0-14 Years)
- 2.4.2 Adolescent and Young Adult Population (15-39 Years)
- 2.4.3 Adult Population (40-64 Years)
- 2.4.4 Geriatric Population (65 Years and Above)
2.5 Global Cancer Incidence Analysis
- 2.5.1 Incidence by Tumor Type
- 2.5.2 Incidence by Gender
- 2.5.3 Incidence by Age Cohort
2.6 Cancer Prevalence Analysis
- 2.6.1 Five-Year Prevalence
- 2.6.2 Long-Term Survivorship Trends
2.7 Mortality Analysis
- 2.7.1 Age-Specific Mortality Trends
- 2.7.2 Cancer-Specific Mortality Analysis
2.8 Survival Rate Analysis
- 2.8.1 Pediatric Survival Trends
- 2.8.2 Adult Oncology Survival Trends
- 2.8.3 Geriatric Survival Outcomes
2.9 Risk Factor Assessment
- 2.9.1 Tobacco Use
- 2.9.2 Alcohol Consumption
- 2.9.3 Obesity and Metabolic Disorders
- 2.9.4 Occupational and Environmental Exposure
- 2.9.5 Genetic and Hereditary Factors
2.10 Epidemiology of Major Cancer Types by Age Group
- 2.10.1 Breast Cancer
- 2.10.2 Lung Cancer
- 2.10.3 Colorectal Cancer
- 2.10.4 Prostate Cancer
- 2.10.5 Leukemia
- 2.10.6 Lymphoma
- 2.10.7 Brain and Central Nervous System Tumors
- 2.10.8 Cervical Cancer
- 2.10.9 Liver Cancer
- 2.10.10 Gastric Cancer
2.11 Screening and Diagnosis Trends by Age Group
2.12 Healthcare Burden and Economic Impact
2.13 Unmet Epidemiological Needs

3. Market Dynamics

3.1 Market Overview
3.2 Market Drivers
- 3.2.1 Increasing Global Cancer Burden
- 3.2.2 Aging Population and Rising Geriatric Oncology Cases
- 3.2.3 Expansion of Precision Oncology
- 3.2.4 Increasing Screening and Awareness Programs
- 3.2.5 Growing Adoption of Biomarker-Based Diagnostics
3.3 Market Restraints
- 3.3.1 High Cost of Oncology Treatment
- 3.3.2 Limited Access in Low- and Middle-Income Regions
- 3.3.3 Delayed Diagnosis in Pediatric and Geriatric Populations
- 3.3.4 Regulatory and Reimbursement Challenges
3.4 Market Opportunities
- 3.4.1 AI-Based Cancer Diagnostics
- 3.4.2 Expansion of Cell and Gene Therapies
- 3.4.3 Personalized Oncology Therapeutics
- 3.4.4 Growth in Home-Based Cancer Monitoring
3.5 Market Challenges
- 3.5.1 Clinical Trial Recruitment Complexity by Age Group
- 3.5.2 Treatment Toxicity in Elderly Patients
- 3.5.3 Drug Resistance and Disease Recurrence
3.6 Porter's Five Forces Analysis
3.7 PESTLE Analysis
3.8 Value Chain Analysis
3.9 Stakeholder Analysis

4. Commercial & Market Access

4.1 Reimbursement Landscape
- 4.1.1 Public Reimbursement Programs
- 4.1.2 Private Insurance Coverage
- 4.1.3 Value-Based Oncology Care Models
4.2 Pricing Analysis of Oncology Therapeutics
4.3 Health Technology Assessment Trends
4.4 Access to Pediatric Oncology Care
4.5 Access to Geriatric Oncology Treatment
4.6 Patient Assistance Programs
4.7 Distribution and Procurement Models
4.8 Hospital and Specialty Pharmacy Trends
4.9 Real-World Evidence in Market Access Decisions

5. Innovation & Pipeline Landscape

5.1 Oncology Innovation Overview
5.2 Pipeline Overview by Development Phase
- 5.2.1 Phase I Pipeline Candidates
- 5.2.2 Phase II Pipeline Candidates
- 5.2.3 Phase III Pipeline Candidates
5.3 Pipeline Analysis by Mechanism of Action
- 5.3.1 PD-1/PD-L1 Inhibitors
- 5.3.2 CTLA-4 Inhibitors
- 5.3.3 HER2-Targeted Therapies
- 5.3.4 EGFR Inhibitors
- 5.3.5 PARP Inhibitors
- 5.3.6 Antibody-Drug Conjugates
- 5.3.7 CAR-T Cell Therapies
- 5.3.8 Bispecific Antibodies
- 5.3.9 Cancer Vaccines
5.4 Pipeline Analysis by Modality
- 5.4.1 Small Molecules
- 5.4.2 Monoclonal Antibodies
- 5.4.3 Cell Therapies
- 5.4.4 Gene Therapies
- 5.4.5 RNA-Based Therapeutics
5.5 Biomarker and Companion Diagnostic Developments
5.6 Artificial Intelligence in Oncology Research
5.7 Clinical Trial Trends by Age Group
5.8 Strategic Collaborations and Licensing Agreements
5.9 Patent Landscape Analysis

6. Treatment Landscape

6.1 Current Standard of Care
6.2 Treatment Algorithm by Cancer Type
6.3 Chemotherapy Landscape
6.4 Immunotherapy Landscape
6.5 Targeted Therapy Landscape
6.6 Hormonal Therapy Landscape
6.7 Radiation Therapy Trends
6.8 Surgical Oncology Trends
6.9 Pediatric Oncology Treatment Approaches
6.10 Adolescent and Young Adult Oncology Care
6.11 Geriatric Oncology Treatment Considerations
6.12 Combination Therapy Trends
6.13 Emerging Treatment Paradigms
6.14 Companion Diagnostics and Precision Medicine

7. Cancer Epidemiology by Age Group Report Size & Forecast

7.1 Global Market Overview
7.2 Historical Market Analysis
7.3 Forecast Methodology
7.4 Market Forecast by Age Group
- 7.4.1 Pediatric Population
- 7.4.2 Adolescent and Young Adult Population
- 7.4.3 Adult Population
- 7.4.4 Geriatric Population
7.5 Market Forecast by Cancer Type
7.6 Market Forecast by Treatment Type
7.7 Market Forecast by Diagnostic Modality
7.8 Market Forecast by End User
7.9 Market Forecast by Distribution Channel
7.10 Epidemiology-Driven Market Forecast Assumptions

8. Cancer Epidemiology by Age Group Report Segmentation

8.1 By Cancer Type
- 8.1.1 Breast Cancer
- 8.1.2 Lung Cancer
- 8.1.3 Colorectal Cancer
- 8.1.4 Prostate Cancer
- 8.1.5 Hematologic Malignancies
- 8.1.6 Gynecologic Cancers
- 8.1.7 Gastrointestinal Cancers
- 8.1.8 Neurological Tumors
8.2 By Age Group
- 8.2.1 Pediatric
- 8.2.2 Adolescent and Young Adult
- 8.2.3 Adult
- 8.2.4 Geriatric
8.3 By Therapy Type
- 8.3.1 Chemotherapy
- 8.3.2 Immunotherapy
- 8.3.3 Targeted Therapy
- 8.3.4 Hormonal Therapy
- 8.3.5 Cell and Gene Therapy
8.4 By Drug Class
- 8.4.1 Immune Checkpoint Inhibitors
- 8.4.2 Tyrosine Kinase Inhibitors
- 8.4.3 PARP Inhibitors
- 8.4.4 Monoclonal Antibodies
- 8.4.5 Antibody-Drug Conjugates
8.5 By Route of Administration
- 8.5.1 Oral
- 8.5.2 Intravenous
- 8.5.3 Subcutaneous & Intrathecal
8.6 By End User
- 8.6.1 Hospitals
- 8.6.2 Specialty Cancer Centers
- 8.6.3 Academic and Research Institutes
- 8.6.4 Others
8.7 By Distribution Channel
- 8.7.1 Hospital Pharmacies
- 8.7.2 Retail Pharmacies & Specialty Pharmacies
- 8.7.3 Online Pharmacies

9. Geographical Analysis (Regional Level)

9.1 North America
- 9.1.1 Regional Market Size and Forecast
- 9.1.2 Epidemiology Trends by Age Group
- 9.1.3 Regional Demand Drivers
- 9.1.4 Regulatory Overview
- 9.1.5 Competitive Intensity
9.2 Europe
- 9.2.1 Regional Market Size and Forecast
- 9.2.2 Epidemiology Trends by Age Group
- 9.2.3 Regional Demand Drivers
- 9.2.4 Regulatory Overview
- 9.2.5 Competitive Intensity
9.3 Asia-Pacific
- 9.3.1 Regional Market Size and Forecast
- 9.3.2 Epidemiology Trends by Age Group
- 9.3.3 Regional Demand Drivers
- 9.3.4 Regulatory Overview
- 9.3.5 Competitive Intensity
9.4 Latin America
- 9.4.1 Regional Market Size and Forecast
- 9.4.2 Epidemiology Trends by Age Group
- 9.4.3 Regional Demand Drivers
- 9.4.4 Regulatory Overview
- 9.4.5 Competitive Intensity
9.5 Middle East & Africa
- 9.5.1 Regional Market Size and Forecast
- 9.5.2 Epidemiology Trends by Age Group
- 9.5.3 Regional Demand Drivers
- 9.5.4 Regulatory Overview
- 9.5.5 Competitive Intensity

10. Key Countries Analysis

10.1 United States
- 10.1.1 Market Size and Forecast
- 10.1.2 Cancer Epidemiology by Age Group
- 10.1.3 FDA Regulatory Framework
- 10.1.4 Reimbursement Environment
- 10.1.5 Key Companies and Product Presence
10.2 Canada
- 10.2.1 Market Size and Forecast
- 10.2.2 Cancer Epidemiology by Age Group
- 10.2.3 Regulatory Framework
- 10.2.4 Reimbursement Environment
- 10.2.5 Key Companies and Product Presence
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
- 10.8.1 Market Size and Forecast
- 10.8.2 Cancer Epidemiology by Age Group
- 10.8.3 NMPA Regulatory Framework
- 10.8.4 Reimbursement Environment
- 10.8.5 Key Companies and Product Presence
10.9 Japan
- 10.9.1 Market Size and Forecast
- 10.9.2 Cancer Epidemiology by Age Group
- 10.9.3 PMDA Regulatory Framework
- 10.9.4 Reimbursement Environment
- 10.9.5 Key Companies and Product Presence
10.10 India
- 10.10.1 Market Size and Forecast
- 10.10.2 Cancer Epidemiology by Age Group
- 10.10.3 CDSCO Regulatory Framework
- 10.10.4 Reimbursement Environment
- 10.10.5 Key Companies and Product Presence
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa

11. Regulatory & Policy Landscape

11.1 Overview of Global Oncology Regulatory Frameworks
11.2 United States Regulatory Environment
- 11.2.1 U.S. Food and Drug Administration (FDA)
- 11.2.2 Accelerated Approval Pathways
- 11.2.3 Orphan Drug Designation
11.3 Europe Regulatory Environment
- 11.3.1 European Medicines Agency (EMA)
- 11.3.2 EU Oncology Regulations
- 11.3.3 Pediatric Investigation Plans
11.4 Japan Regulatory Environment
- 11.4.1 Pharmaceuticals and Medical Devices Agency (PMDA)
- 11.4.2 Oncology Drug Approval Process
11.5 India Regulatory Environment
- 11.5.1 Central Drugs Standard Control Organization (CDSCO)
- 11.5.2 Clinical Trial Regulations
11.6 China Regulatory Environment
- 11.6.1 National Medical Products Administration (NMPA)
- 11.6.2 Accelerated Oncology Review Programs
11.7 International Clinical Trial Regulations
11.8 Pharmacovigilance and Safety Monitoring
11.9 Intellectual Property and Patent Protection
11.10 Data Privacy and Oncology Research Compliance

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Strategic Positioning of Leading Players
12.4 Product Portfolio Analysis
12.5 Oncology Pipeline Competitiveness
12.6 Mergers and Acquisitions
12.7 Licensing and Collaboration Activities
12.8 Research and Development Investments
12.9 Manufacturing and Supply Chain Strategies
12.10 SWOT Analysis of Major Players

13. Company Profiles

13.1 Roche Holding
- 13.1.1 Company Overview
- 13.1.2 Approved Oncology Products
  - 13.1.2.1 Avastin (bevacizumab)
  - 13.1.2.2 Herceptin (trastuzumab)
  - 13.1.2.3 Tecentriq (atezolizumab)
- 13.1.3 Key Oncology Indications
- 13.1.4 Verified Oncology Pipeline Assets
13.2 Merck & Co.
- 13.2.1 Company Overview
- 13.2.2 Approved Oncology Products
  - 13.2.2.1 Keytruda (pembrolizumab)
- 13.2.3 Key Oncology Indications
- 13.2.4 Verified Oncology Pipeline Assets
13.3 Bristol Myers Squibb
- 13.3.1 Approved Oncology Products
  - 13.3.1.1 Opdivo (nivolumab)
  - 13.3.1.2 Yervoy (ipilimumab)
13.4 AstraZeneca
- 13.4.1 Approved Oncology Products
  - 13.4.1.1 Tagrisso (osimertinib)
  - 13.4.1.2 Imfinzi (durvalumab)
13.5 Pfizer
- 13.5.1 Approved Oncology Products
  - 13.5.1.1 Ibrance (palbociclib)
  - 13.5.1.2 Adcetris (brentuximab vedotin)
13.6 Novartis
- 13.6.1 Approved Oncology Products
  - 13.6.1.1 Kymriah (tisagenlecleucel)
  - 13.6.1.2 Kisqali (ribociclib)
13.7 Johnson & Johnson
- 13.7.1 Approved Oncology Products
  - 13.7.1.1 Darzalex (daratumumab)
  - 13.7.1.2 Erleada (apalutamide)
13.8 Gilead Sciences
- 13.8.1 Approved Oncology Products
  - 13.8.1.1 Trodelvy (sacituzumab govitecan)
  - 13.8.1.2 Yescarta (axicabtagene ciloleucel)
13.9 Amgen
- 13.9.1 Approved Oncology Products
  - 13.9.1.1 Blincyto (blinatumomab)
  - 13.9.1.2 Lumakras (sotorasib)
13.10 Eli Lilly and Company
- 13.10.1 Approved Oncology Products
  - 13.10.1.1 Verzenio (abemaciclib)
  - 13.10.1.2 Jaypirca (pirtobrutinib)
13.11 Comparative Company Benchmarking
13.12 Pipeline Competitiveness Comparison

14. Future Outlook

14.1 Future Trends in Cancer Epidemiology
14.2 Impact of Aging Population on Oncology Burden
14.3 Future of Precision Oncology
14.4 AI and Digital Oncology Integration
14.5 Emerging Biomarker Trends
14.6 Future Clinical Trial Design Evolution
14.7 Opportunities in Pediatric and Geriatric Oncology
14.8 Strategic Recommendations for Stakeholders
14.9 Long-Term Market Outlook

15. Methodology

15.1 Research Methodology Overview
15.2 Secondary Research Sources
15.3 Primary Research Methodology
15.4 Epidemiology Modeling Approach
15.5 Market Forecasting Techniques
15.6 Data Validation and Triangulation
15.7 Assumptions and Limitations
15.8 Abbreviations and Definitions
15.9 Currency Conversion and Standardization Methods